It is thus expected that naproxen may reduce the mortality associated with critical COVID‐19 patients via both COX‐independent antiviral transcription/replication and COX‐2‐dependent anti‐inflammatory effects (https://clinicaltrials.gov/ct2/show/NCT04325633). This evidence concerns the gene PTGS2 and COVID-19.